Simultaneous Elimination of Reactive Oxygen Species and Activation of Nrf2 by Ultrasmall Nanoparticles to Relieve Acute Kidney Injury
Source abstract
Abstract
Excess reactive oxygen species (ROS) can induce serious acute kidney injury (AKI) to result in numerous deaths annually in clinical practice. Elimination of excess ROS by advanced nanotechnology is a very promising AKI therapy. In this Article, we report that PVP-stabilized and quercetin-functionalized ultrasmall Cu 2– x Se nanoparticles (abbreviated as CSPQ NPs) can efficiently scavenge ROS and increase the expression of intracellular antioxidative enzymes by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) protein, which drastically alleviates the cellular oxidative stress. Our ultrasmall nanoparticles exhibit excellent biocompatibility. They can be rapidly accumulated into the injured kidney to simultaneously eliminate ROS and activate Nrf2 to improve the renal function. This work demonstrates the great potential of simultaneous elimination of ROS and activation of intracellular Nrf2 in treatment of AKI. It also highlights the potential of CSPQ NPs in protection and prevention of AKI.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Acute Kidney Injury Research · Dialysis and Renal Disease Management · Heme Oxygenase-1 and Carbon Monoxide
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, P. R. China
Center for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Suzhou Medical College of Soochow University, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Suzhou 215123, P. R. China
Funding
Ministry of Science and Technology of the People's Republic of China · State Key Laboratory of Radiation Medicine and Protection · Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions · National Natural Science Foundation of China · Priority Academic Program Development of Jiangsu Higher Education Institutions · Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection
References (60)
Show source-provided references
1. 10.1016/j.ejphar.2008.02.08510.1016/j.ejphar.2008.02.085 ↗
2. 10.1146/annurev-pharmtox-010919-02365410.1146/annurev-pharmtox-010919-023654 ↗
3. 10.1016/j.kint.2019.05.02610.1016/j.kint.2019.05.026 ↗
4. 10.1136/bmj.k489110.1136/bmj.k4891 ↗
5. 10.2215/CJN.1129082110.2215/CJN.11290821 ↗
6. 10.2215/CJN.1631122110.2215/CJN.16311221 ↗
7. Malek M. · J. Renal Inj. Prev. · 2015 · 4 · 20
8. 10.1186/s13613-020-0645-110.1186/s13613-020-0645-1 ↗
9. 10.1016/S0140-6736(19)32563-210.1016/S0140-6736(19)32563-2 ↗
10. 10.7326/AITC20171107010.7326/AITC201711070 ↗
11. 10.1681/ASN.200409074010.1681/ASN.2004090740 ↗
12. 10.1016/S0140-6736(13)60647-910.1016/S0140-6736(13)60647-9 ↗
13. 10.1016/S0140-6736(11)61454-210.1016/S0140-6736(11)61454-2 ↗
14. 10.3389/fchem.2020.0073210.3389/fchem.2020.00732 ↗
15. 10.1038/s41563-019-0378-410.1038/s41563-019-0378-4 ↗
16. 10.1038/s41578-021-00328-610.1038/s41578-021-00328-6 ↗
17. 10.1038/s41580-020-0230-310.1038/s41580-020-0230-3 ↗
18. 10.1016/j.molcel.2021.08.01810.1016/j.molcel.2021.08.018 ↗
19. 10.7150/thno.4039510.7150/thno.40395 ↗
20. 10.1002/advs.20200042010.1002/advs.202000420 ↗
21. 10.1007/BF0068532610.1007/BF00685326 ↗
22. 10.1016/j.pharmthera.2013.09.00610.1016/j.pharmthera.2013.09.006 ↗
23. 10.1038/s41467-020-16544-710.1038/s41467-020-16544-7 ↗
24. 10.1016/j.cej.2020.12737110.1016/j.cej.2020.127371 ↗
25. 10.1016/j.biomaterials.2021.12070610.1016/j.biomaterials.2021.120706 ↗
26. 10.1038/s41467-018-07890-810.1038/s41467-018-07890-8 ↗
27. 10.1002/advs.20210149810.1002/advs.202101498 ↗
28. 10.1038/s41551-018-0317-810.1038/s41551-018-0317-8 ↗
29. 10.1021/acsnano.1c0727010.1021/acsnano.1c07270 ↗
30. 10.1002/advs.20200042010.1002/advs.202000420 ↗
31. 10.1016/j.freeradbiomed.2020.06.02510.1016/j.freeradbiomed.2020.06.025 ↗
32. 10.1016/j.freeradbiomed.2015.05.03410.1016/j.freeradbiomed.2015.05.034 ↗
33. 10.1039/C3NP70065H10.1039/C3NP70065H ↗
34. 10.1002/med.2125710.1002/med.21257 ↗
35. 10.1021/jf203800d10.1021/jf203800d ↗
36. 10.1016/j.redox.2019.10127510.1016/j.redox.2019.101275 ↗
37. 10.1016/j.lfs.2020.11858110.1016/j.lfs.2020.118581 ↗
38. 10.1016/j.tox.2014.01.00810.1016/j.tox.2014.01.008 ↗
39. 10.1152/ajprenal.00353.201010.1152/ajprenal.00353.2010 ↗
40. 10.1159/00048773510.1159/000487735 ↗
41. 10.1007/s11033-019-04853-010.1007/s11033-019-04853-0 ↗
42. 10.1016/j.phymed.2022.15430610.1016/j.phymed.2022.154306 ↗
43. 10.1038/s41467-021-21714-210.1038/s41467-021-21714-2 ↗
44. 10.1039/C9NR02884F10.1039/C9NR02884F ↗
45. 10.1016/j.molstruc.2021.13110710.1016/j.molstruc.2021.131107 ↗
46. 10.1016/j.jinorgbio.2019.03.00410.1016/j.jinorgbio.2019.03.004 ↗
47. 10.1021/jacs.0c0939010.1021/jacs.0c09390 ↗
48. 10.1016/j.fct.2017.10.04210.1016/j.fct.2017.10.042 ↗
49. 10.1016/j.biocel.2006.07.00110.1016/j.biocel.2006.07.001 ↗
50. 10.1038/nrm224010.1038/nrm2240 ↗
51. 10.1039/D1CS00044F10.1039/D1CS00044F ↗
52. 10.1002/adfm.20190483310.1002/adfm.201904833 ↗
53. 10.1016/j.nantod.2023.10177010.1016/j.nantod.2023.101770 ↗
54. 10.1021/nl080561510.1021/nl0805615 ↗
55. 10.3390/metabo1206056410.3390/metabo12060564 ↗
56. 10.1007/s12072-021-10144-310.1007/s12072-021-10144-3 ↗
57. 10.1016/S0140-6736(15)60126-X10.1016/S0140-6736(15)60126-X ↗
58. 10.1021/acsnano.8b0679510.1021/acsnano.8b06795 ↗
59. 10.1002/adma.20160219310.1002/adma.201602193 ↗
60. 10.1016/j.nantod.2022.10160110.1016/j.nantod.2022.101601 ↗